Clinical trials: Neuroectodermal Tumors
Diffuse Intrinsic Pontine Glioma, Anaplastic Astrocytoma
Lenalidomide and Radiation Therapy in High Grade Gliomas or Diffuse Intrinsic Pontine Gliomas
Background: Children who are diagnosed with brain tumors known as high grade gliomas or diffuse intrinsic pontine gliomas are generally treated with radiation therapy and chemotherapy.
- Conditions
- Diffuse Intrinsic Pontine Glioma, Anaplastic Astrocytoma, High Grade Glioma
- Trial name
- NCT01222754
- Testing
- Lenalidomide, XRT, 54-59.4 Gy
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- National Cancer Institute (NCI)
Oncolytic Virus, Diffuse Intrinsic Pontine Glioma
Oncolytic Virus Ad-TD-nsIL12 for Primary Pediatric Diffuse Intrinsic Pontine Glioma
This is a drug safety assessment clinical trial with a 3+3 dose escalation design, to observe the safety, tolerability and toxicity of a novel oncolytic virus Ad-TD-nsIL12 intratumoral injection in primary DIPG patients…
- Conditions
- Oncolytic Virus, Diffuse Intrinsic Pontine Glioma, Adverse Drug Event
- Trial name
- NCT05717712
- Testing
- Ad-TD-nsIL12
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Capital Medical University
Neuroblastoma, Osteosarcoma
Study of the Safety and Efficacy of Humanized 3F8 Bispecific Antibody (Hu3F8-BsAb) in Patients With Relapsed/Refractory Neuroblastoma, Osteosarcoma and Other Solid Tumor Cancers
The purpose of this study is to test the safety of a study drug called humanized 3F8 bispecific antibody (Hu3F8-BsAb).
- Conditions
- Neuroblastoma, Osteosarcoma, Other Solid Tumor Cancers
- Trial name
- NCT03860207
- Testing
- Humanized 3F8 Bispecific Antibody, Blood draw
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Y-mAbs Therapeutics
Cancer
Voriconazole Compared With Itraconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
RATIONALE: Antifungals, such as voriconazole and itraconazole, may be effective in preventing fungal infections in patients who are undergoing allogeneic stem cell transplantation.
- Trial name
- NCT00079222
- Testing
- itraconazole, voriconazole
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Recurrent or Refractory Solid Tumors, Ewing Sarcoma
Phase 1 Dose-escalating Study of MM-398 (Irinotecan Sucrosofate Liposome Injection) Plus Intravenous Cyclophosphamide in Recurrent or Refractory Pediatric Solid Tumors
This is a Phase 1 study of the combination of two drugs: MM-398 and Cyclophosphamide. The goal is to find the highest dose of MM-398 that can be given safely when it is used together with the chemotherapy drug Cyclophosphamide.
- Conditions
- Recurrent or Refractory Solid Tumors, Ewing Sarcoma, Rhabdomyosarcoma, Neuroblastoma
- Trial name
- NCT02013336
- Testing
- MM-398 (Irinotecan Sucrosofate Liposome Injection) plus cyclophosphamide
- Where
- 5 sites in United States
- Volunteers
- 30 people
- Sponsor
- South Plains Oncology Consortium
Trilateral Retinoblastoma, Retinoblastoma
Trilateral Retinoblastoma: Incidence and Outcomes
Patients with heritable retinoblastoma are at risk to develop an intracranial brain tumor, which is often fatal. The investigators intend to look at the incidence and survival of trilateral retinoblastoma (which is a brain tumor…
- Trial name
- GS-TRIO (NCT06367530)
- Testing
- Incidence and survival of trilateral retinoblastoma and the differences globally
- Where
- Netherlands
- Volunteers
- 4,351 people
- Sponsor
- Amsterdam UMC, location VUmc
Relapsed or Refractory Solid Tumors or Lymphoma in Children, Neuroblastoma
Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients
This study is designed to investigate whether the use of copanlisib is safe, feasible and beneficial to pediatric patients with solid solid tumors or lymphoma that are recurrent or refractory to standard therapy.
- Conditions
- Relapsed or Refractory Solid Tumors or Lymphoma in Children, Neuroblastoma, Osteosarcoma, Rhabdomyosarcoma
- Trial name
- NCT03458728
- Testing
- Copanlisib (BAY806946)
- Where
- 14 sites in United States
- Volunteers
- 31 people
- Sponsor
- Bayer
Neuroblastoma
Beta-Glucan and Monoclonal Antibody 3F8 in Treating Patients With Metastatic Neuroblastoma
RATIONALE: Beta-glucan may stimulate the immune system and stop tumor cells from growing. Monoclonal antibodies, such as 3F8, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00492167
- Testing
- beta-glucan, monoclonal antibody 3F8, immunohistochemistry staining method
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Glioma, Diffuse Intrinsic Pontine Glioma
A Study of Panobinostat in Combination With Everolimus for Children and Young Adults With Gliomas
This phase 2 trial will evaluate the activity of Panobinostat in combination with Everolimus for children with gliomas harboring H3.1 or H3.3K27M mutation, including newly diagnosed high-grade glioma or DIPG (diffuse intrinsic…
- Trial name
- NCT03632317
- Testing
- Panobinostat, Everolimus
- Where
- United States
- Sponsor
- University of Michigan Rogel Cancer Center
Melanoma
Yervoy® Postmarketing Surveillance for Patients in Japan With Unresectable, Malignant Melanoma
This study is a local, prospective, non-interventional, non-controlled, multicenter, observational study (regulatory postmarketing surveillance).
- Trial name
- NCT02717364
- Where
- 2 sites in Japan
- Volunteers
- 556 people
- Sponsor
- Bristol-Myers Squibb
Neoplasms
A Study of BXQ-350 in Children and Young Adults With Relapsed Solid Tumors
This study will evaluate the safety of BXQ-350 and determine the maximum tolerated dose (MTD) in children and young adults with relapsed solid tumors, including recurrent malignant brain tumors.
- Trial name
- KOURAGE (NCT03967093)
- Testing
- BXQ-350
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- Bexion Pharmaceuticals, Inc.
Melanoma
A Retrospective Observational Study on the Long-term Effects of Ipilimumab-treated Pediatric Participants in the Dutch Melanoma Treatment Registry (DMTR)
This is an observational, national, retrospective study consisting of pediatric patients with advanced (spread or unremoveable) melanoma identified in the DMTR in the Netherlands
- Trial name
- NCT04196452
- Testing
- Ipilimumab
- Volunteers
- 10 people
- Sponsor
- Bristol-Myers Squibb
Glioblastoma Multiforme
Neoadjuvant Nivolumab in Glioblastoma
Neoadjuvant nivolumab will be administered to patients with primary and recurrent glioblastoma multiforme that require surgery. Nivolumab will be continued following surgery.
- Trial name
- Neo-nivo (NCT02550249)
- Testing
- Nivolumab
- Where
- Spain
- Volunteers
- 29 people
- Sponsor
- Clinica Universidad de Navarra, Universidad de Navarra
Diffuse Intrinsic Pontine Glioma or Glioblastoma
Immune Modulatory DC Vaccine Against Brain Tumor
This study is designed to treat patients who have been diagnosed with brain cancer, including glioblastoma (GBM) and diffuse intrinsic pontine glioma (DIPG).
- Trial name
- NCT03914768
- Testing
- Immunomodulatory DC vaccine to target DIPG and GBM
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Shenzhen Geno-Immune Medical Institute
High Grade Glioma, Diffuse Intrinsic Pontine Glioma
A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion
This is a pilot study that will evaluate disease status in children that have been newly diagnosed high-grade glioma with TRK fusion. The evaluation will occur after 2 cycles of the medication (Larotrectinib) have been given.
- Trial name
- NCT04655404
- Testing
- Larotrectinib, Larotrectinib surgical
- Where
- 21 sites in United States, Australia and 3 more
- Volunteers
- 15 people
- Sponsor
- Nationwide Children's Hospital
Ewing Sarcoma, Ewing Family of Tumors
A Trial For Participants With Ewing's Sarcoma Treated With Vigil in Combination With Irinotecan and Temozolomide
The goal of this clinical trial was to compare participants with first relapse or refractory Ewing's sarcoma when treated with investigational product (Vigil) in addition to the standard treatment of irinotecan and temozolomide…
- Conditions
- Ewing Sarcoma, Ewing Family of Tumors, Ewing's Tumor Metastatic, Ewing's Sarcoma Metastatic
- Trial name
- VITA (NCT03495921)
- Testing
- Vigil, Irinotecan, Temozolomide
- Where
- 15 sites in United States
- Volunteers
- 32 people
- Sponsor
- Gradalis, Inc.
Sarcoma
Exatecan Mesylate in Treating Patients With Ewing's Sarcoma, Primitive Neuroectodermal Tumor, or Desmoplastic Small Round Cell Tumor
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of exatecan mesylate in treating patients who have…
- Trial name
- NCT00055952
- Testing
- exatecan mesylate
- Where
- 9 sites in United States, Canada
- Sponsor
- Daiichi Sankyo
High Grade Glioma
Antineoplaston Therapy in Treating Children With Recurrent or Refractory High-Grade Glioma
RATIONALE: Current therapies for children with recurrent/progressive high grade gliomas provide very limited benefit to the patient.
- Trial name
- NCT00003535
- Testing
- Antineoplaston therapy (Atengenal + Astugenal)
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Burzynski Research Institute
High Risk HLA-A2+ Melanoma, Metastatic Disease
Modified Melanoma Vaccine for High Risk or Low Residual Disease Patients
This study is based on the hypothesis that stimulation of the immune response against the tumor can help destroy residual tumor in melanoma patients with very high risk for disease recurrence and in patients with relatively low…
- Trial name
- NCT01861938
- Testing
- Melanoma vaccine modified to express HLA A2/4-1BB ligand
- Sponsor
- Hadassah Medical Organization
Histological, Molecular Sequence Variation
Histomolecular Profiles of Gliomas in Children and Adolescent/Young Adults
In the last decades, many advances have been made in the field of genetic abnormalities of glial and glioneuronal brain tumors. In the 2016 World Health organization (WHO) Classification of Tumors of the Central Nervous System…
- Conditions
- Histological, Molecular Sequence Variation, Glioma
- Trial name
- BioMol GLIOMA (NCT04916015)
- Where
- France
- Volunteers
- 128 people
- Sponsor
- Centre Hospitalier Universitaire, Amiens
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.